dsm-firmenich secures victory in patent infringement litigation against Anhui Tiger Companies related to the production of biotin


Royal dsm-firmenich, a global science-based company in Nutrition, Health and Sustainable Living, announces that it has secured victory in court against Anhui Tiger Biochemical Co., Ltd. and Anhui Tiger Vitamin Industry Co., Ltd. (“Tiger”). According to the judgement, recently confirmed by Supreme People’s Court, Tiger can no longer make an important biotin intermediate using a dsm-firmenich patented process, nor make biotin using that prepared intermediate. The lawsuit relates to dsm-firmenich’s Chinese patent number ZL 200480008505.7 that claims a process for the stereoselective synthesis of an intermediate used in the production of biotin.

The Chinese courts have confirmed the strength and relevance of our patent and have ordered Tiger to immediately stop its infringing activities regarding biotin production and pay dsm-firmenich damages. As a lead innovator in the biotin field, we take our intellectual property seriously and have a zero-tolerance policy against any infringing acts without an express license to use our patented technology,” said Stefan Scheuplein, Vice President Category Water Soluble Vitamins at dsm-firmenich. “dsm-firmenich continues to consider its options with respect to other competitors and will take action against anyone that infringes its patent. If biotin customers have concerns whether this judgement impacts their biotin supply, they should contact their current supplier and/or dsm-firmenich immediately.”

Published on

28 February 2021


  • Press release
  • Vitamins

Media Contact

Mirelle van der Kreeft - Global Communication Manager

+31 6 1038 1639


You are being redirected.

We detected that you are visitng this page from United States. Therefore we are redirecting you to the localized version.